SCHEMBL3014572

SCHEMBL3014572

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.46
LMNA P02545 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 3/20 0.44
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TRPV4 Q9HBA0 1/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 3/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 2/20 0.41
LPAR1 Q92633 1/20 0.40
LPAR2 Q9HBW0 1/20 0.40
HSD11B1 P28845 1/20 0.39
GAA P10253 1/20 0.39
KDM2B Q8NHM5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002069 0.93 TRPV4 (0.43) ACLYLMNAALDH1A1MAPK1POLB
SCHEMBL3002351 0.93 LMNA (0.48) ACLYLMNAALDH1A1MAPK1POLB
SCHEMBL3021382 0.91 TRPV4 (0.48) LMNAALDH1A1MAPK1POLBSMN1; SMN2
SCHEMBL3014738 0.91 KMT2A (0.53) LMNAALDH1A1MAPK1POLBSMN1; SMN2
SCHEMBL3015667 0.91 POLB (0.41) ACLYLMNAALDH1A1MAPK1POLB
SCHEMBL3001076 0.91 TDP1 (0.46) LMNAALDH1A1MAPK1POLBSMN1; SMN2
SCHEMBL3009296 0.91 MAPT (0.48) ACLYLMNAALDH1A1MAPK1POLB
SCHEMBL3009736 0.90 MAPT (0.47) ACLYLMNAALDH1A1MAPK1POLB
SCHEMBL3013342 0.90 TRPV4 (0.45) ALDH1A1POLBSMN1; SMN2TRPV4LPAR1
SCHEMBL3015465 0.90 TRPV4 (0.45) LMNAMAPK1POLBSMN1; SMN2TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ACLY 4592/4885LMNA 80/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.